Creative Medical Technology Holdings, Inc. (CELZ)
- Previous Close
2.5500 - Open
2.5050 - Bid --
- Ask --
- Day's Range
2.4301 - 2.6094 - 52 Week Range
2.4101 - 10.2812 - Volume
23,126 - Avg. Volume
37,139 - Market Cap (intraday)
4.45M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.8000 - Earnings Date Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.00
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
www.creativemedicaltechnology.comRecent News: CELZ
View MorePerformance Overview: CELZ
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CELZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CELZ
View MoreValuation Measures
Market Cap
4.45M
Enterprise Value
-1.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
323.93
Price/Book (mrq)
0.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.27%
Return on Equity (ttm)
-57.03%
Revenue (ttm)
11k
Net Income Avi to Common (ttm)
-5.32M
Diluted EPS (ttm)
-3.8000
Balance Sheet and Cash Flow
Total Cash (mrq)
6.26M
Total Debt/Equity (mrq)
0.22%
Levered Free Cash Flow (ttm)
-3.66M